November 30, 2017
ViiV kicks off third phase of HIV prevention study in women
ViiV Healthcare on Thursday announced the start of HPTN 084,a phase III study to evaluate long-acting cabotegravir for the prevention of…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: HIV
October 4, 2017
Gilead, MPP: single-tablet regimen has potential to simplify the management of HIV
The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United…
September 26, 2017
Janssen files NDA to U.S. FDA for the first Darunavir-based tablet for HIV-1
Janssen has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for darunavir several doses, for…
July 27, 2017
Bavarian Nordic to receive milestone payments up to $836 million from Janssen
Bavarian Nordic has announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals, which grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two programs, targeting vaccines against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1).
June 9, 2017
FDA approves first generic of drug for prevention of HIV and to treat HIV-1
The U.S. Food and Drug Administration has approved the first generic version of Gilead’s Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.
February 15, 2017
Gilead reports results from HIV treatment study at CROI 2017
Gilead Sciences has announced data from two Phase 3 studies evaluating the safety and efficacy of Genvoya for the treatment of HIV-1 infection in treatment-naïve adults.
February 14, 2017
ViiV Healthcare studies on treating HIV with two drug regimen
ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).
February 14, 2017
Gilead to present preclinical HIV study at CROI 2017
Gilead Sciences will present findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment, at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
January 10, 2017
Abivax cashes €8.4 million from Bpifrance for antiviral drugs research
Abivax said on Tuesday it would receive €8.4 million from “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA).
November 1, 2016
USFDA opens door to $30M market for India’s Strides Shasun’s HIV-1 infection tablets
India’s Strides Shasun Limited has received approval from the USFDA for Abacavir Tablets